A Multicenter Cross-Sectional Study of the Swiss Cohort of LAMA2-Related Muscular Dystrophy
This study describes the Swiss cohort of patients with LAMA2-RD and gives insights into measuring disease severity and disease progression, which is important for future clinical trials, as well as for a better clinical understanding and management of patients with LAMA2-RD.
Authors
- Katarzyna Pośpieszny (ORCID: https://orcid.org/0000-0001-7336-3521)
- Mirjam Fink
- Christiane Zweier (ORCID: https://orcid.org/0000-0001-8002-2020)
- Andrea Klein (ORCID: https://orcid.org/0000-0003-2733-5911)
- Georg Martin Stettner (ORCID: https://orcid.org/0000-0002-0906-8816)
- Paolo Ripellino (ORCID: https://orcid.org/0000-0002-8662-9656)
- Cornelia Enzmann (ORCID: https://orcid.org/0000-0002-6780-3348)
- Dominique Baumann
- Elea Galiart
- Joël Fluss (ORCID: https://orcid.org/0000-0002-6413-162X)
- Leonie Steiner
- Bettina Henzi
- David Jacquier (ORCID: https://orcid.org/0000-0002-6173-2905)
- Kevin Plattner (ORCID: https://orcid.org/0000-0002-2414-9593)
Institutions
- University of Bern (CH)
- University of Basel (CH)
- University of Zurich (CH)
- University Hospital of Bern (CH)
- Laboratory for Biomedical Neurosciences (CH)
- University Hospital of Geneva (CH)
- University Children’s Hospital Basel (CH)
- University Children's Hospital Zurich (CH)
- Institute of Social and Preventive Medicine (CH)
- Kantonsspital Aarau (CH)
- Università della Svizzera italiana (CH)
- University of Lausanne (CH)
Publication Details
- Journal
- Journal of Neuromuscular Diseases
- Published
- 2024-08-30
- DOI
- https://doi.org/10.3233/jnd-240023
- Citations
- 1
- Primary Topic
- Muscle Physiology and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.23
Funders
- Pfizer
- Biogen
- Stiftung für die Erforschung der Muskelkrankheiten
- PTC Therapeutics
- AveXis
- Sarepta Therapeutics